Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Phase 1/2 Clinical Study Data on ADXS-HPV in HPV-Associated Anal Cancer Selected for Oral Presentation Keynote Speech to be Delivered by Samir N. Khleif, M.D., Member of Advaxis's Board of...
-
PRINCETON, N.J., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that it has executed definitive...
-
PRINCETON, N.J., Feb. 13, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo...
-
PRINCETON, N.J., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial...
-
PRINCETON, N.J., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced an update related to the Phase 2...
-
PRINCETON, N.J., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug...
-
Company to Provide Comprehensive Review of Lm-LLO Immunotherapy Pipeline and Clinical Studies Six Clinical Investigators to Present and Participate in Question and Answer Session PRINCETON,...
-
PRINCETON, N.J., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it will present at the...
-
Multiple Clinical Milestones Anticipated in 2015 Involving Lm-LLO Cancer Immunotherapy Pipeline Merck and MedImmune Checkpoint Inhibitor Combination Programs to Commence in Q1 2015 Four new...
-
PRINCETON, N.J., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it is entering into a...